<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374280</url>
  </required_header>
  <id_info>
    <org_study_id>GuangzhouMC</org_study_id>
    <nct_id>NCT03374280</nct_id>
  </id_info>
  <brief_title>Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC</brief_title>
  <official_title>The Phase Three Trials of Pemetrexed/Cisplatin Intercalating Gefitinib vs Pemetrexed/Cisplatin Treating EGFR Wild NSCLC(Non Squamous Cell Carcinoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the curative effect between Pemetrexed/Cisplatin and Pemetrexed/Cisplatin
      intercalating Gefitinib Treating EGFR Wild NSCLC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In preclinical data, it is identified that pemetrexed combined with erlotinib could achieve
      good response than pemetrexed because EGFR-TKI (erlotinib) could enhance the sensitivity of
      pemetrexed. So we design the trial to investigate curative effect between
      Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild
      NSCLC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>the last patient into group for three years or dead</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>the last patients into group for 5 years or dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side-effects</measure>
    <time_frame>3 years</time_frame>
    <description>the last patient into group for 3 years or dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>3 years</time_frame>
    <description>the last patient into group for 3 years or dead</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>pemetrexed/cisplatin intercalating gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 ;gefitinib 250mg d3-20d, to 4 cycles.
pemetrexed 500mg/m2 d1; gefitinib 250mg d2-20d to disease progression or untolerable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pemetrexed/cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 to 4 cycles. pemetrexed 500mg/m2 d1 to disease progression or untolerable</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed/cisplatin intercalating gefitinib</intervention_name>
    <arm_group_label>pemetrexed/cisplatin intercalating gefitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed/cisplatin</intervention_name>
    <arm_group_label>pemetrexed/cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Histological or cytological diagnosis of small-cll lung cancer histology

        2.18 years or older

        3.Eastern Cooperative Oncology Group (ECOG) Performance Status no more than 2

        4.Local stage SCLC without distant metastases

        5.After 1st-line chemotherapy (EP or IP) at least 4 cycles

        6.After radical radiotherapy for primary tumor and lymph node drainage area:including
        concurrent or sequence chemoradiotherapy

        7.CR or PR assessment by RECIST(1.0) before randomized

        8.Haemoglobin 10.0 g/dl, Absolute neutrophil count (ANC) 1.5^9/L, platelets 100 x 10^9/L

        9.Total bilirubin 1.5 x upper limit of normal (ULN) alanine aminotransferase (ALT) and
        aspartate aminotransferase (AST) &lt; 2.5 x ULN in the absence of liver metastases, or &lt; 5 x
        ULN in case of liver metastases

        10.Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula)

        Exclusion Criteria:

          1. Mixed non-small cell lung cancer histology

          2. Neck and supraclavicular lymph node metastasis

          3. Be allergic to temozolomide or intolerable to radiotherapy

          4. Any unstable systemic disease

          5. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiajia Yu, MD</last_name>
    <role>Study Director</role>
    <affiliation>the ethics committee of the first affiliated hospital of Guangzhou MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hailing Yang, MD</last_name>
    <phone>00862083062825</phone>
    <email>bjrf2009@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fengnan Wang, MD</last_name>
    <phone>00862083062825</phone>
    <email>wangfengnan@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of Guangzhou MC</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haihong Yang, MD</last_name>
      <phone>0862083062825</phone>
      <email>bjrf2009@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Haihong Yang, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Haihong Yang, MD, Pricipal investigator</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>non small cell lung cancer</keyword>
  <keyword>Gefitinib</keyword>
  <keyword>EGFR negative</keyword>
  <keyword>Pemetrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

